| Merck & Co., Inc26 programs in shared conditions | 24 · 10 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Endometrial Neoplasms +21 | patritumab deruxtecan, sacituzumab tirumotecan, Anti-CD19/CD3 Bispecific Antibody MK-1045 +7 | - AstraZeneca’s trastuzumab deruxtecan vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT05048797)
- AstraZeneca’s rilvegostomig vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT06868277)
- Merck & Co., Inc’s nemtabrutinib vs acalabrutinib (US & EU rights: AstraZeneca) (Leukemia, Lymphocytic, Chronic, B-Cell, NCT06136559)
- and 9 more
|
| Bristol-Myers Squibb26 programs in shared conditions | 16 · 8 with both in phase 3Carcinoma, Non-Small-Cell Lung, Lupus Erythematosus, Systemic, Multiple Myeloma +13 | Nivolumab, izalontamab brengitecan, pumitamig +6 | - AstraZeneca’s datopotamab deruxtecan vs Albumin-Bound Paclitaxel (EU rights: Bristol-Myers Squibb) (Breast Neoplasms, NCT05374512)
- AstraZeneca’s trastuzumab deruxtecan vs Albumin-Bound Paclitaxel (EU rights: Bristol-Myers Squibb) (Breast Neoplasms, NCT04494425)
- AstraZeneca’s volrustomig vs Albumin-Bound Paclitaxel (EU rights: Bristol-Myers Squibb) (Carcinoma, Non-Small-Cell Lung, NCT03819465)
- and 9 more
|
| Eli Lilly and Company38 programs in shared conditions | 20 · 10 with both in phase 3Atherosclerosis, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung +17 | lepodisiran, muvalaplin, tersolisib +8 | - AstraZeneca’s saruparib in a combination vs abemaciclib (US & EU rights: Eli Lilly and Company) (Breast Neoplasms, NCT06380751)
- AstraZeneca’s camizestrant added to abemaciclib (US & EU rights: Eli Lilly and Company) (Breast Neoplasms, NCT06380751)
- AstraZeneca’s camizestrant added to abemaciclib (US & EU rights: Eli Lilly and Company) (Breast Neoplasms, NCT04964934)
- and 9 more
|
| Johnson & Johnson17 programs in shared conditions | 10 · 6 with both in phase 3Carcinoma, Non-Small-Cell Lung, Leukemia, Lymphocytic, Chronic, B-Cell, Lupus Erythematosus, Systemic +7 | lazertinib, amivantamab, ibrutinib +4 | - AstraZeneca’s acalabrutinib vs ibrutinib (EU rights: Johnson & Johnson) (Leukemia, Lymphocytic, Chronic, B-Cell, NCT02477696)
- AstraZeneca’s Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT07391657)
- AstraZeneca’s Actinium-225 vs apalutamide (US & EU rights: Johnson & Johnson) (Prostatic Neoplasms, NCT07611110)
- and 5 more
|
| Otsuka Holdings Co., Ltd.9 programs in shared conditions | 9 · 3 with both in phase 3Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Glomerulonephritis, IGA +6 | zimberelimab, futibatinib, zipalertinib +1 | - Otsuka Holdings Co., Ltd.’s futibatinib in a combination vs durvalumab (US & EU rights: AstraZeneca) (Biliary Tract Neoplasms, NCT07710885)
- Otsuka Holdings Co., Ltd.’s zimberelimab in a combination vs durvalumab (US & EU rights: AstraZeneca) (Biliary Tract Neoplasms, NCT07710885)
- AstraZeneca’s rilvegostomig added to Tegafur (most trials: Otsuka Holdings Co., Ltd.) (Biliary Tract Neoplasms, NCT06109779)
- and 5 more
|